Qualitee 360 excels at placing products in the care environment to identify maximum value. We also provide consultation and tools to determine how to improve product performance and overall value. Our Quality Improvement initiatives are supported by complex data analysis systems which are built for this very purpose.
Quality Improvement Projects utilize real-world data collection that takes place throughout a patient’s entire cycle of care. Rather than using traditional clinical research – data collected in an isolated, controlled setting – employing a QI process allows us to observe on both a local and a global scale how drugs, devices and methods of care affect real patients every day.
The Problem - There is a growing need within healthcare device and pharmaceutical companies to continually evolve products, advance technique, improve clinical outcomes and reduce costs. Until now, companies could only get feedback from surgeons considered key opinion leaders.
The Solution - Qualitee 360 helps companies access the clinical process from the most important perspective: the patient's. We bring a network of thought leaders, surgeons, specialty-focused scientists and engineers who understand existing clinical challenges and the limitations of current medical products from first-hand experience. It is with this insight that Qualitee 360 offers a comprehensive range of services that medical manufacturers, pharmaceutical companies and distributors can employ regardless of where they are in the product development process.
The Results - Clinical data, based upon actual clinical care, gives companies the most valuable perspective in healthcare. It leads to new opportunities for product innovation, improvements and segmentation. Medical device manufacturers, pharmaceutical companies and distributors use the findings uncovered by Qualitee 360 to improve target marketing efforts including physician education and adoption. Having access to the patient processes and overall system functions can help companies identify gaps and areas where innovation could produce improved clinical and financial outcomes. Alternatively, companies can learn where their product may cause harm and put them in a position to mitigate risks and advise against certain uses.
